MOCCIA, MARIALUISA
MOCCIA, MARIALUISA
Istituto di Endocrinologia e Oncologia Sperimentale ''G. Salvatore'' - IEOS
D898_E901 RET Deletion Is Oncogenic, Responds to Selpercatinib, and Treatment Resistance Can Arise Via RET-Independent Mechanisms
2023 Porcelli, Tommaso; Moccia, Marialuisa; De Stefano, Maria Angela; Ambrosio, Raffaele; Capoluongo, Ettore; Santoro, Massimo; Hadoux, Julien; Schlumberger, Martin; Carlomagno, Francesca; Salvatore, Domenico
Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
2022 Zhang, Lingtian; Moccia, Marialuisa; Briggs, David C.; Bharate, Jaideep B.; Lakkaniga, Naga Rajiv; Knowles, Phillip; Yan, Wei; Tran, Phuc; Kharbanda, Anupreet; Wang, Xiuqi; Leung, Yuet-Kin; Frett, Brendan; Santoro, Massimo; Mcdonald, Neil Q.; Carlomagno, Francesca; Li, Hong-yu
Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation
2021 Yan, Wei; Zhang, Lingtian; Lv, Fengping; Moccia, Marialuisa; Carlomagno, Francesca; Landry, Christophe; Santoro, Massimo; Gosselet, Fabien; Frett, Brendan; Li, Hong-yu
Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases
2021 Moccia, Marialuisa; Yang, Donglin; Lakkaniga, Naga Rajiv; Frett, Brendan; Mcconnell, Nicholas; Zhang, Lingtian; Brescia, Annalisa; Federico, Giorgia; Zhang, Lingzhi; Salerno, Paolo; Santoro, Massimo; Li, Hong-yu; Carlomagno, Francesca
Bioisosteric discovery of npa101.3, a second-generation ret/vegfr2 inhibitor optimized for single-agent polypharmacology
2020 Moccia, M; Frett, B; Zhang, L; Lakkaniga, Nr; Briggs, Dc; Chauhan, R; Brescia, A; Federico, G; Yan, W; Santoro, M; Mcdonald, Nq; Li, Hy; Carlomagno, F
Ret gene fusions in malignancies of the thyroid and other tissues
2020 Santoro, M; Moccia, M; Federico, G; Carlomagno, F
Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology
2015 Frett, Brendan; Carlomagno, Francesca; Moccia Maria, Luisa; Brescia, Annalisa; Federico, Giorgia; DE FALCO, Valentina; Admire, Brittany; Chen, Zhongzhu; Qi, Wenqing; Santoro, Massimo; Li, Hongyu
Identification of novel small molecule inhibitors of oncogenic RET kinase
2015 Moccia, M; Liu, Q; Guida, T; Federico, G; Brescia, A; Zhao, Z; Choi, Hg; Deng, X; Tan, L; Wang, J; Billaud, M; Gray, Ns; Carlomagno, F; Santoro, M
Identification of two novel RET kinase inhibitors through MCR-based drug discovery: Design, synthesis and evaluation
2014 Frett, B; Moccia, M; Carlomagno, F; Santoro, M; Li, Hy
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| D898_E901 RET Deletion Is Oncogenic, Responds to Selpercatinib, and Treatment Resistance Can Arise Via RET-Independent Mechanisms | 1-gen-2023 | Porcelli, Tommaso; Moccia, Marialuisa; De Stefano, Maria Angela; Ambrosio, Raffaele; Capoluongo, Ettore; Santoro, Massimo; Hadoux, Julien; Schlumberger, Martin; Carlomagno, Francesca; Salvatore, Domenico | |
| Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose | 1-gen-2022 | Zhang, Lingtian; Moccia, Marialuisa; Briggs, David C.; Bharate, Jaideep B.; Lakkaniga, Naga Rajiv; Knowles, Phillip; Yan, Wei; Tran, Phuc; Kharbanda, Anupreet; Wang, Xiuqi; Leung, Yuet-Kin; Frett, Brendan; Santoro, Massimo; Mcdonald, Neil Q.; Carlomagno, Francesca; Li, Hong-yu | |
| Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation | 1-gen-2021 | Yan, Wei; Zhang, Lingtian; Lv, Fengping; Moccia, Marialuisa; Carlomagno, Francesca; Landry, Christophe; Santoro, Massimo; Gosselet, Fabien; Frett, Brendan; Li, Hong-yu | |
| Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases | 1-gen-2021 | Moccia, Marialuisa; Yang, Donglin; Lakkaniga, Naga Rajiv; Frett, Brendan; Mcconnell, Nicholas; Zhang, Lingtian; Brescia, Annalisa; Federico, Giorgia; Zhang, Lingzhi; Salerno, Paolo; Santoro, Massimo; Li, Hong-yu; Carlomagno, Francesca | |
| Bioisosteric discovery of npa101.3, a second-generation ret/vegfr2 inhibitor optimized for single-agent polypharmacology | 1-gen-2020 | Moccia, M; Frett, B; Zhang, L; Lakkaniga, Nr; Briggs, Dc; Chauhan, R; Brescia, A; Federico, G; Yan, W; Santoro, M; Mcdonald, Nq; Li, Hy; Carlomagno, F | |
| Ret gene fusions in malignancies of the thyroid and other tissues | 1-gen-2020 | Santoro, M; Moccia, M; Federico, G; Carlomagno, F | |
| Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology | 1-gen-2015 | Frett, Brendan; Carlomagno, Francesca; Moccia Maria, Luisa; Brescia, Annalisa; Federico, Giorgia; DE FALCO, Valentina; Admire, Brittany; Chen, Zhongzhu; Qi, Wenqing; Santoro, Massimo; Li, Hongyu | |
| Identification of novel small molecule inhibitors of oncogenic RET kinase | 1-gen-2015 | Moccia, M; Liu, Q; Guida, T; Federico, G; Brescia, A; Zhao, Z; Choi, Hg; Deng, X; Tan, L; Wang, J; Billaud, M; Gray, Ns; Carlomagno, F; Santoro, M | |
| Identification of two novel RET kinase inhibitors through MCR-based drug discovery: Design, synthesis and evaluation | 1-gen-2014 | Frett, B; Moccia, M; Carlomagno, F; Santoro, M; Li, Hy |